Radiopharmaceuticals

#Bristol Myers Squibb #Mergers and acquisitions #Radiopharmaceuticals #RayzeBio

Bristol Myers Squibb buys radiopharmaceuticals company

Bristol Myers Squibb has completed its acquisition of RayzeBio for approximately $4.1 billion, adding radiopharmaceutical therapeutics (RPTs) to its pipeline. Chris Boerner, Chief Executive Officer, Bristol Myers Squibb, said: “By strengthening and further diversifying our oncology pipeline beyond I-O, we will unlock exciting opportunities that support BMS’s growth in the… Read More

#Business & Investment #News

Peptide
#Endocrinology #FDA #Oncology #Orano Med #RadioMedix #Radiopharmaceuticals

First targeted alpha therapy receives breakthrough designation

The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to AlphaMedix (212Pb-DOTAMTATE) for the treatment of adult patients with unresectable or metastatic, progressive somatostatin receptor expressing gastroenteropancreatic neuroendocrine tumours (GEP-NETs) who are naïve to peptide receptor radionuclide therapy (PRRT). AlphaMedix is a targeted alpha therapy currently in… Read More

#Cancer Research #News #Regulatory

Theranostic radiopharmaceuticals
#Ariceum Therapeutics #Cancer treatment #Radiopharmaceuticals

In Conversation With: Manfred Ruediger, CEO of Ariceum

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.    In this episode, Megan Thomas is in conversation with Manfred Ruediger, CEO of… Read More

#News

Corporate collaboration
#Cancer #Orano Med #Orbit Discovery #Peptides #Radiopharmaceuticals

Collaboration to discover novel targeted radioligand therapies

Orano Med, a biotechnology company developing Lead-212 (212Pb) targeted alpha therapy against cancer, and Orbit Discovery, a company discovering therapeutic peptide hits, have entered into a collaboration to discover specific peptide receptor radionuclide therapies (PRRT) against cancer cells and advance the development of novel radiopharmaceuticals.   Under… Read More

#Cancer Research #News

Lungs
#Ariceum Therapeutics #Lung cancer #Murdoch University Health Center #Radiopharmaceuticals #Small cell lung cancer #Theranostics

First patient dosed in Phase Ib study in small cell lung cancer 

Ariceum Therapeutics, a biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, has dosed the first patient with its first-in-class lead molecule, satoreotide, targeting extensive stage small cell lung cancer (ES-SCLC), at the Murdoch University Health Center in Perth, Australia.  Ariceum has… Read More

#News

#Ariceum Therapeutics #Cancer research #Meet the Researcher #Radiopharmaceuticals

Meet the researcher: Germo Gericke, Ariceum Therapeutics

Germo Gericke, Ariceum Therapeutics, tells DDW's Megan Thomas about his work in radiopharmaceuticals for the treatment of cancer and offers valuable advice to others in this field. 1. Where do you work, and can you tell us what you’re working on at the moment? I am the Chief Medical Officer… Read More

#Cancer Research #Exclusive Content #Opinion

handshake
#Acquisition #PARP inhibitors #Radiopharmaceuticals #Tumours

Ariceum Therapeutics expands pipeline with acquisition 

Ariceum Therapeutics, a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, has acquired Theragnostics, a UK-based private biopharmaceutical company engaged in the development of radio-labelled PARP inhibitors for the diagnosis and treatment of tumours.  The acquisition provides Ariceum with an… Read More

#News